Literature DB >> 23248310

Interferon-γ mediates chemokine-dependent recruitment of natural killer cells during viral infection.

Melissa A Pak-Wittel1, Liping Yang, Dorothy K Sojka, Joshua G Rivenbark, Wayne M Yokoyama.   

Abstract

Natural killer (NK) cells provide in vivo control of orthopoxvirus infections in association with their expansion in the draining lymph node (LN), where they are normally very rare. The mechanism of this expansion is unclear. Herein, we determined that NK-cell depletion results in enhanced infection following footpad inoculation of cowpox virus, a natural pathogen of rodents. Following cowpox virus infection in normal mice, NK cells were greatly expanded in the draining LN, were not replicating, and displayed markers similar to splenic NK cells, suggesting specific recruitment of splenic NK cells rather than in situ proliferation. Moreover, NK-cell expansion was abrogated by prior injection of clodronate-loaded liposomes, indicating a role for subcapsular sinus macrophages. Furthermore, recruitment of transferred splenic NK cells to the draining LN was pertussis toxin-sensitive, suggesting involvement of chemokine receptors. Comprehensive analysis of chemokine mRNA expression in the draining LN following infection suggested the selective involvement of CCR2, CCR5, and/or CXCR3. Mice deficient for CCR2 or CCR5 had normal NK-cell recruitment, whereas CXCR3-deficient mice displayed a major defect, which was NK cell-intrinsic. Interestingly, both induction of transcripts for CXCR3 ligands (Cxcl9 and Cxcl10) and NK-cell recruitment required IFN-γ. These data indicate that NK-cell recruitment is mediated by subcapsular sinus macrophages, IFN-γ, and CXCR3 during orthopoxvirus infection.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23248310      PMCID: PMC3538256          DOI: 10.1073/pnas.1220456110

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  67 in total

1.  Cowpox: reservoir hosts and geographic range.

Authors:  J Chantrey; H Meyer; D Baxby; M Begon; K J Bown; S M Hazel; T Jones; W I Montgomery; M Bennett
Journal:  Epidemiol Infect       Date:  1999-06       Impact factor: 2.451

2.  The chemokines CXCL9 and CXCL10 promote a protective immune response but do not contribute to cardiac inflammation following infection with Trypanosoma cruzi.

Authors:  Jenny L Hardison; Ruth A Wrightsman; Philip M Carpenter; Thomas E Lane; Jerry E Manning
Journal:  Infect Immun       Date:  2006-01       Impact factor: 3.441

3.  Blockade of chemokine activity by a soluble chemokine binding protein from vaccinia virus.

Authors:  A Alcamí; J A Symons; P D Collins; T J Williams; G L Smith
Journal:  J Immunol       Date:  1998-01-15       Impact factor: 5.422

4.  Transmission of monkeypox among persons exposed to infected prairie dogs in Indiana in 2003.

Authors:  James C Kile; Aaron T Fleischauer; Bradley Beard; Matthew J Kuehnert; Richard S Kanwal; Pamela Pontones; Hans J Messersmith; Robert Teclaw; Kevin L Karem; Zachary H Braden; Inger Damon; Ali S Khan; Marc Fischer
Journal:  Arch Pediatr Adolesc Med       Date:  2005-11

Review 5.  Natural killer cells in antiviral defense: function and regulation by innate cytokines.

Authors:  C A Biron; K B Nguyen; G C Pien; L P Cousens; T P Salazar-Mather
Journal:  Annu Rev Immunol       Date:  1999       Impact factor: 28.527

6.  Monocyte chemoattractant protein-1 and CCR2 interactions are required for IFN-alpha/beta-induced inflammatory responses and antiviral defense in liver.

Authors:  Kirsten L Hokeness; William A Kuziel; Christine A Biron; Thais P Salazar-Mather
Journal:  J Immunol       Date:  2005-02-01       Impact factor: 5.422

7.  Induction of cytokine expression by herpes simplex virus in human monocyte-derived macrophages and dendritic cells is dependent on virus replication and is counteracted by ICP27 targeting NF-kappaB and IRF-3.

Authors:  Jesper Melchjorsen; Jukka Sirén; Ilkka Julkunen; Søren R Paludan; Sampsa Matikainen
Journal:  J Gen Virol       Date:  2006-05       Impact factor: 3.891

8.  Induced recruitment of NK cells to lymph nodes provides IFN-gamma for T(H)1 priming.

Authors:  Alfonso Martín-Fontecha; Lindy L Thomsen; Sara Brett; Craig Gerard; Martin Lipp; Antonio Lanzavecchia; Federica Sallusto
Journal:  Nat Immunol       Date:  2004-11-07       Impact factor: 25.606

9.  Vaccinia, cowpox, and camelpox viruses encode soluble gamma interferon receptors with novel broad species specificity.

Authors:  A Alcamí; G L Smith
Journal:  J Virol       Date:  1995-08       Impact factor: 5.103

10.  A chemokine-binding domain in the tumor necrosis factor receptor from variola (smallpox) virus.

Authors:  Alí Alejo; M Begoña Ruiz-Argüello; Yin Ho; Vincent P Smith; Margarida Saraiva; Antonio Alcami
Journal:  Proc Natl Acad Sci U S A       Date:  2006-03-31       Impact factor: 12.779

View more
  51 in total

1.  The genetic background influences the cellular and humoral immune responses to vaccines.

Authors:  M Zeng; E Nourishirazi; E Guinet; M Nouri-Shirazi
Journal:  Clin Exp Immunol       Date:  2016-08-16       Impact factor: 4.330

2.  Licensing delineates helper and effector NK cell subsets during viral infection.

Authors:  Anthony E Zamora; Ethan G Aguilar; Can M Sungur; Lam T Khuat; Cordelia Dunai; G Raymond Lochhead; Juan Du; Claire Pomeroy; Bruce R Blazar; Dan L Longo; Jeffrey M Venstrom; Nicole Baumgarth; William J Murphy
Journal:  JCI Insight       Date:  2017-05-18

Review 3.  Chemokine-guided cell positioning in the lymph node orchestrates the generation of adaptive immune responses.

Authors:  Jeffrey Lian; Andrew D Luster
Journal:  Curr Opin Cell Biol       Date:  2015-06-08       Impact factor: 8.382

4.  Murine liver-resident group 1 innate lymphoid cells regulate optimal priming of anti-viral CD8+ T cells.

Authors:  Peter D Krueger; Sowmya Narayanan; Fionna A Surette; Michael G Brown; Sun-Sang J Sung; Young S Hahn
Journal:  J Leukoc Biol       Date:  2016-08-04       Impact factor: 4.962

5.  α2β1 Integrin Is Required for Optimal NK Cell Proliferation during Viral Infection but Not for Acquisition of Effector Functions or NK Cell-Mediated Virus Control.

Authors:  Colby Stotesbury; Pedro Alves-Peixoto; Brian Montoya; Maria Ferez; Savita Nair; Christopher M Snyder; Shunchuan Zhang; Cory J Knudson; Luis J Sigal
Journal:  J Immunol       Date:  2020-02-03       Impact factor: 5.422

6.  The effects of prebiotics on microbial dysbiosis, butyrate production and immunity in HIV-infected subjects.

Authors:  S Serrano-Villar; J F Vázquez-Castellanos; A Vallejo; A Latorre; T Sainz; S Ferrando-Martínez; D Rojo; J Martínez-Botas; J Del Romero; N Madrid; M Leal; J I Mosele; M J Motilva; C Barbas; M Ferrer; A Moya; S Moreno; M J Gosalbes; V Estrada
Journal:  Mucosal Immunol       Date:  2016-12-21       Impact factor: 7.313

7.  Interleukin-2 from Adaptive T Cells Enhances Natural Killer Cell Activity against Human Cytomegalovirus-Infected Macrophages.

Authors:  Zeguang Wu; Giada Frascaroli; Carina Bayer; Tatjana Schmal; Thomas Mertens
Journal:  J Virol       Date:  2015-04-08       Impact factor: 5.103

8.  Natural Killer Cells and Innate Interferon Gamma Participate in the Host Defense against Respiratory Vaccinia Virus Infection.

Authors:  Georges Abboud; Vikas Tahiliani; Pritesh Desai; Kyle Varkoly; John Driver; Tarun E Hutchinson; Shahram Salek-Ardakani
Journal:  J Virol       Date:  2015-10-14       Impact factor: 5.103

9.  Inflammatory Responses of Astrocytes Are Independent from Lipocalin 2.

Authors:  Natalie Gasterich; Sophie Wetz; Stefan Tillmann; Lena Fein; Anke Seifert; Alexander Slowik; Ralf Weiskirchen; Adib Zendedel; Andreas Ludwig; Steffen Koschmieder; Cordian Beyer; Tim Clarner
Journal:  J Mol Neurosci       Date:  2020-09-21       Impact factor: 3.444

10.  Acute clearance of human metapneumovirus occurs independently of natural killer cells.

Authors:  Sherry C Wen; Sharon J Tollefson; Monika Johnson; Pavlo Gilchuk; Kelli L Boyd; Bryan Shepherd; Sebastian Joyce; John V Williams
Journal:  J Virol       Date:  2014-06-25       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.